$MRK News

How Recent Pipeline Bets Are Rewriting the Story for Merck (MRK)

Pfizer vs Merck: Chasing High Yield vs Higher Returns

Merck & Co. (MRK) Announces Quarterly Dividend

Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Jim Cramer Notes “Merck’s Cancer Dominance Has Been Challenged of Late By JNJ”

Merck's Calderasib Gets FDA's Breakthrough Therapy Tag for NSCLC

Merck (MRK) Strengthens Capital Structure With Notes Offering

SMMT Stock Surges Overnight: Cancer Drug Survival Win Raises The Bar As PFE, BMY, MRK Chase Keytruda's Successor

Merck’s (MRK) Deep Drug Pipeline Could Power its Next Chapter

At ASCO, Merck makes case for a ‘cornerstone’ cancer drug

Can MRK's New Drugs & Pipeline Aid Long-Term Growth Post Keytruda LOE?

Is Merck & Co. Stock Outperforming the S&P 500?

FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)

Merck Announces FDA Breakthrough Therapy Designation For Calderasib, An Investigational Oral Specific KRAS G12C Inhibitor, In Combination With Keytruda

Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock

Merck to Participate in the Jefferies Global Healthcare Conference

Merck Announces Third-Quarter 2026 Dividend

Here's Why You Should Add JANX Stock to Your Portfolio Now

Merck Talc Verdict Adds Fresh Liability Question For High Flying Shares

Adcendo ApS Announces Clinical Collaboration and Supply Agreement with MSD to Evaluate ADCE-T02 in Combination with KEYTRUDA® (Pembrolizumab) in a Phase Ib Study in Patients with Advanced Solid Tumors